Capstone Partners advised CorVista Health, Inc. in raising $65 million of Series C equity capital to advance its artificial intelligence-based cardiovascular diagnostic technology, bringing the Company’s total funding to nearly $100 million.
CorVista’s non-invasive point-of-care solution utilizes cloud-based algorithms, enabling physicians to rapidly test for heart disease without the need for radiation, contrast agents or cardiac stress.
Proceeds will be used for acceleration of product development and infrastructure ahead of commercialization, as well as ongoing clinical research to assess coronary artery disease, heart failure and pulmonary hypertension.
The financing was led by Ambix Life Science Fund I, L.P., along with MedVenture Partners, Inc. and several new and previous investors.
Capstone Partners also advised CorVista (previously known as Analytics 4 Life) on its $25.6 million Series B financing.
